Immuno-Oncology | Specialty

Studies of Second-Line Immunotherapies in Bladder Cancer Hold Promise

March 16th 2015

With no major advances in survival in bladder cancer in more than 30 years, interest is high in the potential to deploy immunotherapeutic approaches in this setting.

Gomella Discusses Optimizing Sipuleucel-T in mCRPC

March 16th 2015

In an interview with OncLive, Leonard G. Gomella discusses the benefits, limitations, and considerations of sipuleucel-T for patients with prostate cancer.

Dr. Petrylak on Immunotherapy for Second-line Treatment in Bladder Cancer

March 14th 2015

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the potential for immunotherapy for the treatment of bladder cancer.

Dr. Luke on PD-1 Agents as Frontline Immunotherapy in Melanoma

March 13th 2015

Jason J. Luke, MD, FACP, assistant professor of medicine, Melanoma and Developmental Therapeutics Clinic, University of Chicago Medicine, discusses PD-1 inhibitors nivolumab and pembrolizumab as frontline immunotherapy choices for patients with melanoma.

Dr. Jagannath on Immunotherapy in Multiple Myeloma

March 10th 2015

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses immunotherapy in multiple myeloma and how it fits into the future treatment paradigm.

Dr. Kim on Evolution of Treatment Outcomes in Melanoma

March 7th 2015

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses how treatment outcomes in melanoma have evolved over the last few years.

BMS, Bavarian Nordic Forge Immunotherapy Collaboration

March 5th 2015

A nearly $1 billion windfall licensing agreement involving the immunotherapy PROSTVAC has the company Bavarian Nordic looking toward a long-term manufacturing and distribution arrangement with Bristol-Myers Squibb.

FDA Approves Nivolumab for Lung Cancer

March 4th 2015

Acting 3 months ahead of schedule, the FDA approved nivolumab (Odivo) for patients with squamous non-small cell lung cancer.

FDA Accepts sBLA for Adjuvant Ipilimumab in Melanoma

March 2nd 2015

The FDA has accepted a supplemental Biologics License Application for ipilimumab for the adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

Adding Anti-PD-L1 Antibody to Bevacizumab Induces Responses in mRCC

March 2nd 2015

An investigational antibody that targets programmed death-ligand 1 (PD-L1) in combination with bevacizumab had strong antitumor activity and induced responses in 4 of 10 patients with metastatic renal cell carcinoma (mRCC) in an open-label phase Ib study.

Nivolumab Receives Priority Review for NSCLC

February 27th 2015

The FDA has granted a priority review to nivolumab for use in patients with previously treated, advanced, squamous non–small cell lung cancer.

Five-Year Analysis Shows Ipilimumab More Than Doubles OS in Advanced Melanoma

February 27th 2015

In an analysis of phase III data, the 5-year survival rate with ipilimumab plus dacarbazine in patients with advanced melanoma was 18.2% versus 8.8% with dacarbazine alone.

PD-1 Inhibition Requires Further Refinement in Melanoma

February 25th 2015

In an interview with OncLive, Suzanne L. Topalian, MD, director of the Melanoma Program at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discussed the rapid advance of nivolumab and potential next-steps.

Immunotherapy, Personalized Medicine to Highlight Winter Hematology Meeting

February 20th 2015

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

Dr. Brahmer on Immunotherapy Development in Lung Cancer

February 17th 2015

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses immunotherapy and how it can advance as a treatment option for patients with lung cancer.

FDA Schedules Advisory Meeting for T-VEC in Metastatic Melanoma

February 12th 2015

The FDA has scheduled an advisory hearing to discuss the biologics license application for the immunotherapy talimogene laherparepvec as a treatment for patients with metastatic melanoma.

Dr. Topalian on Biomarkers for Anti- PD-1 Therapies in Melanoma

February 12th 2015

Suzanne Topalian, MD, professor of surgery and oncology, John Hopkins Medicine, and director of the melanoma program, Sidney Kimmel Comprehensive Cancer Center, compares biomarker detection for anti- PD-1 therapies like nivolumab to anti-CTLA-4 therapies like ipilimumab for the treatment of melanoma.

FDA Grants Reolysin Orphan Drug Designation for Ovarian Cancer

February 12th 2015

The FDA has granted an orphan drug designation to Reolysin for the treatment of patients with ovarian cancer.

FDA Grants Breakthrough Status to PD-L1 Inhibitor MPDL3280A in NSCLC

February 2nd 2015

The anti–PD-L1 agent MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer that has progressed during or after platinum-based chemotherapy, as well as a targeted therapy for patients with EGFR- or ALK-positive tumors.

Dr. Jeffrey Weber on Ipilimumab for Melanoma

February 2nd 2015

Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.

NEXT PAGE
PREVIOUS PAGE